ArticleMolecular neurobiology2025
Edaravone Protected from D-Galactose-Induced Cell Senescence via Reduction of DNA Damage and Downregulation of p53, p21 and p16 Genes in PC12 Cells.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence (CS) as an irreversible cell cycle arrest occurs in different tissues and organs. Among the others, CS is one of the most common risk factors for neurodegenerative diseases. The current study aimed to highlight the protective effects of Edaravone (EDN) as a free radical scavenger on D-galactose-induced cell senescence in PC12 cells. CS was induced following 48 h exposure to D-galactose (DG), and the protective effects of EDN at various concentrations (0.1, 1 and 10 µM) were studied. Cell proliferation, oxidative stress biomarkers such as total antioxidant capacity and lipid peroxidation rate, total protein level and protein carbonylation rate, pro-inflammatory cytokines (TNF-α) release, apoptotic cell death biomarkers including caspase 3/7 activities and the expression of p53, p21 and p16 as related genes to CS were analyzed. Experimentally induced CS resulted in a significant (p < 0.05) decrease in cell proliferation, elevation of lipid peroxidation and protein carbonylation rates, increase of TNF-α release, elevation of the number of apoptotic cells and DNA damage, along with 3.4 to 13-fold upregulation of CS-related gene expression. The most practical and effective concentration of EDN to protect PC12 cells from DG-induced injuries was found to be 1 µM. These findings in PC12 cells suggest that EDN with its antioxidant and anti-inflammatory properties could be an effective anti-aging compound to protect cells from various types of DNA-damaging factors.
Indexed as
Identifiers
41254185What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.